TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05006716: A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Sponsor: BeOne Medicines · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 689 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,443,050

Rescue Site Savings

+$5,576,340

Unlock Full NCT05006716 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05006716 Rescue Dossier →